Accéder au contenu
Merck
Toutes les photos(1)

Documents

P3700000

6-Propyl-2-thiouracil

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

6-Propyl-2-thiouracil, 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone, 4-Hydroxy-2-mercapto-6-propylpyrimidine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C7H10N2OS
Numéro CAS:
51-52-5
Poids moléculaire :
170.23
Numéro Beilstein :
130039
Numéro MDL:
MFCD00006041
Code UNSPSC :
41116107
ID de substance PubChem :
329820187
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Description

enzyme inhibitor

Famille d'API

propylthiouracil

Fabricant/nom de marque

EDQM

Pf

218-220 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CCCC1=CC(=O)NC(=S)N1

InChI

1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)

Clé InChI

KNAHARQHSZJURB-UHFFFAOYSA-N

Informations sur le gène

human ... DIO1(1733) , TPO(7173)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Propylthiouracil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H351

Classification des risques

Acute Tox. 4 Oral - Carc. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

L-Thyroxine ≥98% (HPLC)

Sigma-Aldrich

T2376

L-Thyroxine

Eleni Memi et al.
Journal of pediatric endocrinology & metabolism : JPEM, 25(3-4), 331-343 (2012-07-10)
Antithyroid drugs (ATDs) have been widely and effectively used for the treatment of pediatric and adult thyrotoxicosis for more than a half century. Since the very beginning of ATD use, reports of hepatic dysfunction related to propylthiouracil (PTU) therapy have
Spiros Karras et al.
Journal of pediatric endocrinology & metabolism : JPEM, 25(7-8), 623-630 (2012-11-20)
Propylthiouracil (PTU), carbimazole (CMZ) and methimazole (MMI) are the most common drugs used today in cases of adolescent thyrotoxicosis. Skepticism has been growing regarding the use of PTU in childhood and its association with severe liver failure. The aim of
Daniel Glinoer et al.
Current opinion in endocrinology, diabetes, and obesity, 19(5), 402-407 (2012-07-24)
To bring to the attention of healthcare professionals the additional information on propylthiouracil (PTU)-related hepatotoxicity, based on a reanalysis of medical files reported to the Food and Drug Administration (1982-2008) for acute liver failure in PTU-treated hyperthyroid patients, and propose
Long-term propylthiouracil use and acute myeloid leukemia: a case report and review of the literature.
Daniele Focosi et al.
Annals of hematology, 87(3), 233-235 (2007-09-12)
A Rambaldi et al.
Liver, 21(6), 398-404 (2002-03-21)
The aim of this review was to determine the benefits and adverse effects of propylthiouracil for patients with alcoholic liver disease. Systematic Cochrane Review of randomised clinical trials. The Cochrane Hepato-Biliary Controlled Clinical Trials Register, The Cochrane Library, MEDLINE, and
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique